Abstract：
The development of monoclonal antibodies that selectively target IgE and type 2 immunity has opened new possibilities in the treatment of allergies. Although they have been used mainly as single therapies found to have efficacy in the management of asthma and other T2-mediated diseases, there is a growing interest in using these monoclonal antibodies in combination with allergen immunotherapy (AIT). AIT has transformed the treatment of allergic diseases by aiming to modify the underlying immune response to allergens rather than just providing temporary symptom relief. Despite the proven efficacy and safety of AIT, unmet needs call for further research and innovation. Combination strategies involving biologics and AIT exhibit potential in improving short-term efficacy, reducing adverse events, and increasing immunologic tolerance. Anti-IgE emerges as the most promising therapeutic strategy, not only enhancing AIT\'s safety and tolerability but also providing additional evidence of efficacy compared with AIT alone. Anti-interleukin-4 receptor offers a reduction in adverse effects and an improved immunologic profile when combined with AIT; however, its impact on short-term efficacy seems limited. The combination of cat dander subcutaneous immunotherapy with anti-thymic stromal lymphopoietin was synergistic with enhanced efficacy and altered immune responses that persisted for 1 year after discontinuation compared with AIT alone. Long-term studies are needed to evaluate the sustained benefits and safety profiles of combination strategies.
摘要：
选择性靶向IgE和2型免疫的单克隆抗体的开发为治疗过敏开辟了新的可能性。尽管它们主要用作单一疗法，在哮喘和其他T2介导的疾病的管理中显示出疗效，将这些单克隆抗体与变应原免疫疗法(AIT)联合使用越来越有兴趣。AIT通过旨在改变对过敏原的潜在免疫反应而不仅仅是提供暂时的症状缓解,从而改变了过敏性疾病的治疗。尽管AIT的有效性和安全性得到了证实，未满足的需求需要进一步的研究和创新。涉及生物制剂和AIT的组合策略在改善短期疗效方面表现出潜力，减少不良事件，和增加免疫耐受。抗IgE成为最有前途的治疗策略，不仅提高了AIT的安全性和耐受性，而且与单独的AIT相比，还提供了更多的疗效证据。抗IL-4受体与AIT联合使用时可减少副作用并改善免疫学特征，然而，其对短期疗效的影响似乎有限。与单独的AIT相比，猫皮屑皮下免疫疗法与抗TSLP的组合具有协同作用，具有增强的功效和改变的免疫反应，在停药后持续了一年。需要长期研究来评估组合策略的持续益处和安全性。
